Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer

Author: Vandana Singh | July 06, 2021 10:23am

  • Health Canada has approved Puma Biotechnology Inc's (NASDAQ:PBYI) Nerlynx (neratinib) in combination with capecitabine for metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting.
  • Knight Therapeutics Inc (OTC:KHTRF) has the exclusive right to commercialize Nerlynx in Canada.
  • Nerlynx is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2, and HER4. 
  • Price Action: PBYI shares are down 2.49% at $8.60 during the market session on the last check Tuesday.

Posted In: KHTRF PBYI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)
CORE Finalist